

Drug Monograph

Drug Name: **Tirosint[®]-SOL (levothyroxine) oral solution**
 Drug Class: **Endocrine and Metabolic: Thyroid Replacement Therapy**
 Prepared For: MO HealthNet
 Prepared By: Conduent

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: Tirosint-SOL is now available in a 37.5 mcg/ml, 44 mcg/ml, and 62.5 mcg/ml oral solution.

Manufacturer: Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054.

Indications: Tirosint-SOL is indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism.

Costs: \$4.44 per ampule or \$133.20 per 30 ampules. Wholesale Acquisition Cost

Summary of Findings: The MO HealthNet Division recommends prior authorization status for this product.

Status Recommendation: Clinical Edit PA Required
 Open Access PDL

Type of PA Criteria: Appropriate Indications Non-Preferred
 No PA Required Preferred

Prepared by: April Ash, PharmD
 Date: September 1, 2021